This Article  • Abstract  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Cardiovascular System  • Arrhythmias  • Cardiovascular Intervention  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Stroke Prevention in Atrial Fibrillation III Study

The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators

JAMA. 1998;279:1273-1277.

ABSTRACT
Context.— Nonvalvular atrial fibrillation (AF) carries an increased risk for stroke, but absolute rates of stroke vary widely within the broad spectrum of AF patients.

Objective.— To prospectively validate a risk stratification scheme identifying patients with AF with low rates of stroke when given aspirin.

Design.— Prospective cohort study with mean duration of follow-up of 2.0 years, conducted between 1993 and 1997.

Setting.— Outpatient clinics affiliated with academic medical centers.

Patients.— Patients with AF categorized as "low risk" based on the absence of 4 prespecified thromboembolic risk factors: recent congestive heart failure or left ventricular fractional shortening of 25% or less, previous thromboembolism, systolic blood pressure greater than 160 mm Hg, or female sex at age older than 75 years.

Intervention.— All participants given aspirin, 325 mg/d.

Main Outcome Measures.— Ischemic stroke (considered disabling when Rankin score was II or worse 1-3 months later) and systemic embolism (primary events).

Results.— Among 892 participants, the mean (SD) age was 67 (10) years, 78% were men, and histories of hypertension, diabetes, and ischemic heart disease were present in 46%, 13%, and 16%, respectively. The rate of primary events was 2.2% per year (95% confidence interval [CI], 1.6%-3.0%), of ischemic stroke was 2.0% per year (95% CI, 1.5%-2.8%), and of disabling ischemic strokes was 0.8% per year (95% CI, 0.5%-1.3%). Those with a history of hypertension had a higher rate of primary events (3.6% per year) than those with no history of hypertension (1.1% per year) (P<.001). The rate of disabling ischemic stroke was low in those with and without a history of hypertension (1.4% per year and 0.5% per year, respectively). The rate of major bleeding during aspirin therapy was 0.5% per year.

Conclusion.— Patients with AF who have relatively low rates of ischemic stroke, particularly disabling stroke, during treatment with aspirin can be reliably identified.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

NEARLY 2 million Americans have nonvalvular atrial fibrillation (AF),¹ a powerful, independent risk factor for ischemic stroke.² Several randomized clinical trials have demonstrated that treatment with adjusted-dose warfarin reduces the risk of stroke in AF patients by about two thirds,³ leading to current recommendations that most AF patients receive lifelong anticoagulation. The efficacy of aspirin for preventing stroke in AF patients is controversial, but supported by pooled results of 3 placebo-controlled trials yielding a 21% reduction in stroke.⁴ Although clearly less effective than warfarin therapy for prevention of ischemic events, treatment with aspirin carries a lower risk of bleeding and requires less medical monitoring.⁵

Patients with AF are a heterogeneous population, and the absolute rate of stroke varies widely within the broad spectrum of patients with this common dysrhythmia.^6-7 Many patients have a low rate of stroke while taking aspirin or if untreated; anticoagulation of such low-risk patients would offer only small reductions in the absolute rates of stroke.⁵ Although a variety of schemes for stratifying stroke risk in AF patients have been proposed,^{3, 8-11} none has been validated prospectively. Reliable criteria for risk stratification would allow AF patients who benefit most and least from anticoagulation to be identified. We therefore undertook this prospective study to validate a risk stratification scheme by recruiting AF patients who did not have prespecified thromboembolic risk factors, placing them all on aspirin, and assessing the subsequent rate of stroke and systemic embolism.

METHODS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

Patients

Eligible patients were adults with AF documented in the 6 preceding months who did not have prosthetic heart valves, mitral stenosis, or other conditions requiring anticoagulation, contraindications to aspirin, or any of 4 specific risk factors for thromboembolism¹²: (1) impaired left ventricular function manifest by recent (within 100 days) congestive heart failure or reduced fractional shortening (25%) by M-mode echocardiography; (2) systolic blood pressure higher than 160 mm Hg at study entry as determined by 2 blood pressure measurements taken on separate days (1 systolic pressure measurement must have exceeded 160 mm Hg and either the other measurement must have exceeded 150 mm Hg or the patient must have had documented systolic blood pressure in the prior 3 months exceeding 160 mm Hg); (3) prior ischemic stroke, transient ischemic attack (TIA), or systemic embolism; or (4) female and older than 75 years.

Blood pressure was measured in the patient's right arm while sitting after 5 minutes of rest and having had no coffee or tobacco within 1 hour, recording the level of the first Korotkoff sound auscultated during slow deflation of cuff pressure (3 mm/s). Electronically recorded pressures were not allowed. Participants could have a history of hypertension provided that systolic blood pressure was not elevated at the time of screening. Specific criteria for clinical congestive heart failure and echocardiographic measurements have been previously reported.^{9, 13} Patients with "lone AF" (ie, age <60 years without clinical cardiovascular disease or hypertension and a normal echocardiogram) were not enrolled; patients with intermittent AF were eligible.

Participation required signed informed consent according to federal and local regulations governing research involving human subjects, and the protocol was approved by institutional review boards at each participating site. All participants were assigned to receive enteric-coated aspirin, 325 mg/d (Ecotrin, SmithKline Beecham Consumer Brands, Philadelphia, Pa). Outpatients with AF were recruited from 20 clinical sites in the United States and Canada and were screened at public, private, and Veterans Affairs health care facilities.

We hypothesized that AF patients without any of the 4 thromboembolic risk factors would have a rate of ischemic stroke and systemic emboli (primary events) of less than 3% per year. These thromboembolic risk factors were derived from exploratory multivariate analyses of AF patients receiving aspirin in the Stroke Prevention in Atrial Fibrillation (SPAF) I and II studies.¹⁰ The sample size required to exclude a primary event rate of 3% or higher per year was calculated using a Poisson model to estimate the required patient-years of exposure, as reported in detail elsewhere.¹² Prespecified secondary analyses stratified patients according to the presence or absence of a history of hypertension and considered disability associated with ischemic strokes in the evaluation of outcome events.¹²

Physician investigators evaluated potential participants for thromboembolic risk factors. A history of hypertension was recorded either if the patient was receiving medications for treatment of hypertension or if, based on medical records, blood pressure consistently exceeded 160 mm Hg systolic or 90 mm Hg diastolic during at least 3 months of the year prior to enrollment. Twelve-lead electrocardiography (for the presence of AF) and M-mode and 2-dimensional echocardiography (for left ventricular fractional shortening and index) were carried out at entry and interpreted by study-affiliated cardiologists.

Follow-up

Participants were seen in the clinic at 3 months, 6 months, and every 6 months thereafter and were contacted by telephone between visits at 3-month intervals. At clinic visits, blood pressure was measured, and participants were interviewed to detect ischemic events or development of thromboembolic risk factors. Adherence was assessed by pill count; compliance was categorized as good if 80% or more of the expected number of tablets were taken. Participants were withdrawn from study therapy if any of the 4 thromboembolic risk factors were identified (although all patients were followed up until the end of the study). Subsequent antithrombotic therapy was determined by their personal physicians. For withdrawal from study therapy because of systolic hypertension, blood pressure must have exceeded 160 mm Hg and persisted at least 1 week later.

Outcome Measures

Potential events were detected by interviews with study physicians during clinic visits, by interim telephone interviews with research nurses, and by yearly administration of a stroke symptoms questionnaire. All possible strokes, systemic emboli, or TIAs were independently verified by consensus of at least 2 members of an events committee, based on the report of a local study-affiliated neurologist and review of original medical records from which information about antithrombotic therapy was purged. Events committee members were unaware of whether the patient was in this aspirin-treated cohort or a contemporaneous randomized trial.^{12, 14}

Diagnosis of ischemic stroke required focal neurologic symptoms or signs of sudden onset persisting for more than 24 hours. Absence of primary hemorrhage was confirmed by neuroimaging or necropsy in 35 (97%) of 36 patients. When signs and symptoms clinically resolved in 24 hours, a diagnosis of TIA was assigned, even when acute brain infarction was evident by subsequent neuroimaging (delayed neuroimaging was not systematically carried out). Ischemic stroke subtypes were classified as defined previously.¹⁵ A neurologist assessed all patients with stroke 1 to 3 months after the event to evaluate residual disability. Strokes were judged disabling when the modified Rankin score was II (corresponding to restriction in lifestyle that did not prevent living independently) or worse.¹⁶ A diagnosis of systemic embolism was made when there was abrupt vascular insufficiency related to arterial occlusion without previous evidence of atherosclerosis. When sudden vascular occlusion occurred in a limb affected by atherosclerosis, it was categorized as "possibly embolic" if clinical and radiographic features were suggestive of embolic obstruction, but was not counted as a primary event. Major hemorrhage was assessed by the criteria of Landefeld et al.¹⁷

Statistical Analysis

All reported analyses were prespecified, except an exploratory multivariate analysis to identify features associated with primary events during follow-up. This analysis used a forward stepwise procedure with P=.05 to enter the model.

A safety committee not involved in the conduct of the study monitored primary events for unexpectedly high rates. Analyses were intent to treat except where noted. Confidence intervals for event rates were computed using a Poisson distribution. Time to event was computed using product-limit estimates, and Cox proportional hazards models were used to develop multivariate models related to events. Model assumptions were verified by inspection of survival curves. For some secondary analyses, follow-up was censored at the time thromboembolic risk factors were identified by the study investigators. Comparisons of baseline characteristics between groups used the ² test for categorical variables and the Student t test for continuous variables. All tests were 2-sided, and significance was accepted at the P=.05 level.

RESULTS

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

A total of 892 participants were enrolled between May 1993 and November 1996 at 20 clinical centers in the United States and Canada. Their mean (SD) age was 67 (10) years; 78% were men; and histories of hypertension, diabetes, and ischemic heart disease were present in 46%, 13%, and 16%, respectively (Table 1). Medical contraindications to warfarin anticoagulation were present in 2%, while 33% were receiving warfarin prior to enrollment (stopped at study entry). The mean (SD) estimated duration of AF was 7 (9) years (median, 4 years).

View this table: [in this window] [in a new window] Table 1.—Clinical Features of the Participants*

Participants were followed up for a mean of 2.0 years (range, 3 months to 3.9 years); no patients were lost to follow-up. Compliance with aspirin was categorized as good for 86% of follow-up intervals. Risk factors for thromboembolism developed at a rate of 6.5% per year, including congestive heart failure at 3.2% per year, systolic hypertension at 1.4% per year, women reaching the age of 76 years at 0.6% per year, and TIA at 1.4% per year. Other reasons for withdrawal from active status occurred at a rate of 3.9% per year, including participant request (0.4% per year).

The rate of primary events was 2.2% per year (95% confidence interval [CI], 1.6%-3.0%) with no appreciable change in rate during 3 years of follow-up (Table 2, Figure 1). The rate of ischemic stroke was 2.0% per year (95% CI, 1.5%-2.8%), and the rate of disabling ischemic stroke was 0.8% per year (95% CI, 0.5%-1.3%). Transient ischemic attacks occurred at a rate of 1.3% per year; in 2 of 23 patients with clinical TIAs, neuroimaging studies suggested acute brain infarction. The primary event rate was essentially unchanged when follow-up was censored at the time any of the 4 prespecified thromboembolic risk factors were identified (Table 2). Strokes were categorized as probably cardioembolic in 50%, probably noncardioembolic in 25%, and uncertain etiology in 25%, based on neurologic features.

View this table: [in this window] [in a new window] Table 2.—Key Outcomes*

View larger version (5K): [in this window] [in a new window] Kaplan-Meier plot of cumulative percentage of patients free of primary events; vertical lines indicate 95% confidence intervals of product-limit estimates. The maximum exposure was 1405 days.

The rate of primary events among those with a history of hypertension (46% of the cohort) was significantly higher than for remaining participants (3.6% [95% CI, 2.5%-5.2%] vs 1.1% [95% CI, 0.6%-2.0%] per year; P<.001). The rate of disabling ischemic strokes was also higher for those with vs those without a history of hypertension (1.4% [95% CI, 0.8%-2.6%] vs 0.5% [95% CI, 0.2%-1.2%] per year, respectively; P=.05). Multivariate analysis confirmed that a history of hypertension was an independent predictor of primary events (relative risk [RR], 3.3; 95% CI, 1.7-6.9; P=.001); age was the only other statistically significant predictor (RR increase of 1.7 per 10 years; 95% CI, 1.1-2.6; P=.01) in the multivariate model. Other features included in the multivariate model that were not significant predictors were sex, women aged 70 to 75 years, diabetes, ischemic heart disease, remote history of heart failure, current tobacco smoking, blood pressure at entry and during follow-up, fractional shortening of 26% to 30%, left ventricular muscle mass, and left atrial diameter greater than 5.0 cm.

Major bleeding occurred in 13 patients (0.7% per year). Of 11 non–central nervous system (CNS) hemorrhages, 4 occurred while patients were receiving warfarin following withdrawal from aspirin therapy. The rate of non-CNS major bleeding in patients receiving aspirin was 0.4% per year (6 of 7 gastrointestinal hemorrhages).

COMMENT

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

These results suggest that patients with AF can be prospectively identified who have a low risk of stroke, particularly disabling ischemic stroke, when taking aspirin. Such patients may not benefit substantially from treatment with warfarin, since their rate of stroke during aspirin therapy is sufficiently low that warfarin could only minimally reduce the absolute rate of stroke. For those AF patients without a history of hypertension or any of the 4 specific risk factors, the rate of ischemic stroke approximated that of the general population of this age range, about 1% per year.¹⁸ In contrast, AF patients with 1 or more of the 4 thromboembolic risk factors who entered a separate randomized trial component of the SPAF III Study had much higher rates of stroke (averaging 8% per year), even when treated with aspirin in combination with low doses of warfarin.¹⁴ These clinical criteria, applied by nearly 40 study-affiliated physicians at 20 clinical sites, distinguished AF patients with high rates of thromboembolism from those at lower risk, and the stratification appeared durable over 2 to 3 years. Using these criteria, a large fraction of AF patients could be identified who have low to moderate risks of stroke if treated with aspirin alone—about half the participants in earlier SPAF studies^{5, 13} and a similar proportion of a population-based cohort of people with AF (Robert G. Hart, MD, for the Cardiovascular Health Study Investigators, unpublished data, March 1998).

Whether aspirin therapy contributed to the low event rates observed in this study cannot be determined in the absence of an untreated control group. Pooled analysis of 3 randomized trials testing aspirin in AF patients suggests an overall 21% reduction in stroke.⁴ While the rate of major hemorrhage associated with daily use of aspirin in the doses tested in these trials (75-325 mg/d) was similar to that with placebo,^{7, 13} other larger studies suggest that even low doses of aspirin slightly increase the rate of major hemorrhage.¹⁹ Because of the low rates of stroke and major hemorrhage observed in this cohort, direct comparison of aspirin therapy with either warfarin or placebo in randomized trials would require many thousands of participants and could demonstrate only small differences, unlikely to be clinically important.

The relative benefits and risks afforded by aspirin vs placebo or adjusted-dose warfarin were not assessed directly by this study, as all participants received aspirin. Based on other placebo-controlled studies, however, it can be estimated that for every 1000 AF patients without any of the 4 specific risk factors, about 5 ischemic strokes would be prevented and about 3 major hemorrhages would occur each year among those treated with aspirin.^{4, 19} In a low-risk cohort of AF patients defined by our criteria, warfarin treatment instead of aspirin would prevent about 10 ischemic strokes^{3, 20} and cause perhaps 10 to 12 major hemorrhages for every 1000 patients per year.^{5, 13} By comparison, among high-risk AF patients (with 1 or more risk factors), about 60 ischemic strokes would be prevented by using warfarin instead of aspirin for every 1000 treated for 1 year.^{7, 14} These estimates, derived from previous clinical trials, are subject to controversy, particularly those surrounding bleeding rates during anticoagulation in clinical trials vs clinical practice.

The definitions of stroke and systemic embolism were those used in the previous SPAF trials^{5, 13-14} and similar to other recent studies.³ Other vascular events that did not meet these criteria may still be clinically relevant, including TIAs with evidence of acute cerebral infarction by neuroimaging and acute leg artery occlusions in patients with arteriosclerosis. When these events were included, the rate of events was 2.4% per year. On the other hand, the rate of disabling ischemic stroke, even when those resulting in minimal restriction of lifestyle (Rankin score of II) were considered, was relatively low (0.8% per year). In this cohort of AF patients with a low risk of stroke, disabling stroke represented a minority of thromboembolic events, while it comprises a majority of strokes in unselected^{3, 5, 21} and high-risk¹⁴ AF populations. These nondisabling strokes cannot be considered trivial events, but the risk-benefit assessment of antithrombotic options for stroke prevention should consider stroke severity.

Patients with a history of hypertension had a significantly higher rate of ischemic stroke than those without hypertension in a prespecified secondary analysis prompted by earlier analyses of patients receiving aspirin in the SPAF I and II studies.¹⁰ Hypertension has been consistently associated with stroke risk in AF patients^{3, 22} and appears to be associated with an increased risk for cardioembolic stroke in AF patients.¹⁵ While the rate of stroke remained higher for those with a history of hypertension, subgroup analysis of pooled data from 3 randomized trials suggests that aspirin is efficacious for AF patients with a history of hypertension.⁴ It is unknown whether sustained control of hypertension reduces the rate of thromboembolism in AF to that approaching the rate in AF patients without hypertension. The independent influence of patient age on stroke risk in these relatively low-risk AF patients disclosed by the exploratory multivariate analysis supports the findings of others³ and merits additional investigation. Age was not a prespecified risk factor, based on lack of independent predictive value in the derivation data set,¹⁰ and hence we are less confident of its reliability.

It may be clinically useful to stratify AF patients into 3 levels of risk based on our criteria: low (about 1.0% per year) for those without thromboembolic risk factors or hypertension, moderate (about 3.5% per year) for those with a history of hypertension but no other risk factors, and high (about 8% per year) for those with risk factors unless treated with anticoagulation. Whether AF patients at moderate risk of ischemic stroke while receiving aspirin would importantly benefit from adjusted-dose warfarin should take into account patient values and preferences^23-24 as well as the safety of anticoagulation vs aspirin therapy for the individual patient.²⁵ Thromboembolic risk factors were identified during follow-up in 6% per year of participants who were deemed free of them initially, and periodic reassessment to detect thromboembolic risk factors that favor the use of warfarin is important to minimize stroke.

A substantial fraction of the patients with AF, identifiable by specific clinical criteria, have low rates of thromboembolism during aspirin therapy and benefit much less from anticoagulation than would high-risk AF patients. Additional studies of larger cohorts may clarify pathogenic links and refine risk stratification in the future. Furthermore, results of treatment of patients in clinical practice may vary from those in research trials and studies, and additional studies of the application of these criteria in clinical practice would be welcome. To provide optimum patient safety, selection of antithrombotic prophylaxis for AF patients should consider the widely different rates of thromboembolism associated with individual patient features.

AUTHOR INFORMATION

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

A complete list of the SPAF Investigators was published in Lancet (1996;348:633-638).

The Writing Committee for this article (listed alphabetically) assumes responsibility for its scientific content: David C. Anderson, MD, Minneapolis, Minn; Jonathan L. Halperin, MD, New York, NY; Robert G. Hart, MD, San Antonio, Tex; John H. McAnulty, MD, Portland, Ore; Ruth McBride and Lesly A. Pearce, MS, Seattle, Wash; and David G. Sherman, MD, San Antonio.

This work was supported by grant R01 NS24224 from the Division of Stroke and Trauma, National Institute of Neurological Disorders and Stroke, Bethesda, Md.

Reprints: Ruth McBride, SPAF Statistical Coordinating Center, 1107 NE 45th St, Suite 520, Seattle, WA 98105 (e-mail: ruthm{at}sercnw.com).

REFERENCES

Jump to Section  • Top  • Introduction  • Methods  • Results  • Comment  • Author information  • References

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473. FREE FULL TEXT 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988. FREE FULL TEXT 3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457. FREE FULL TEXT 4. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med. 1997;157:1237-1240. FREE FULL TEXT 5. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691. FULL TEXT | ISI | PUBMED 6. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over 3 decades. N Engl J Med. 1987;317:669-674. ABSTRACT 7. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262. ISI | PUBMED 8. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features in patients at risk. Ann Intern Med. 1992;116:1-5. FREE FULL TEXT 9. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features in patients at risk. Ann Intern Med. 1992;116:6-12. FREE FULL TEXT 10. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157. 11. Van Latum JC, Koudstaal PJ, Venables GS, Van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non-rheumatic atrial fibrillation. Stroke. 1995;26:801-806. FREE FULL TEXT 12. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;5:341-353. FULL TEXT 13. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539. FREE FULL TEXT 14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638. FULL TEXT | ISI | PUBMED 15. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32-36. FREE FULL TEXT 16. Bamford JM, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989;20:828. ISI | PUBMED 17. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol. 1989;42:711-718. FULL TEXT | ISI | PUBMED 18. Kronmal RA, Hart RG, Manolio T, et al. Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke. 1998;29:887-894. FREE FULL TEXT 19. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135. ABSTRACT 20. Hart RG. Management of atrial fibrillation. In: Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B, eds. Primer on Cerebrovascular Diseases. New York, NY: Academic Press; 1997:786-791. 21. Lin HJ, Wolf PA, Kelly-Hays M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27:1760-1764. FREE FULL TEXT 22. Flegel KM, Harley J. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. Stroke. 1989;20:1000-1004. FREE FULL TEXT 23. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G. Warfarin for atrial fibrillation: the patient perspective. Arch Intern Med. 1996;156:1841-1848. FREE FULL TEXT 24. Flegel KM, Hutchinson TA, Gromme PA, Tousignant P. Factors relevant to preventing embolic stroke in patients with nonrheumatic atrial fibrillation. J Clin Epidemiol. 1991;44:551-560. FULL TEXT | ISI | PUBMED 25. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1996;156:409-416. FREE FULL TEXT

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Patients With Atrial Fibrillation at Low Risk of Stroke
Raymond Cheung, Daniel E. Singer, Ruth McBride, Robert G. Hart, and Jonathan L. Halperin
JAMA. 1998;280(10):882-883.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Stroke Treatment: Promising but Still Struggling
Louis R. Caplan
JAMA. 1998;279(16):1304-1306.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Crandall et al.
Mayo Clin Proc. 2009;84:643-662.
ABSTRACT | FULL TEXT  

Use of Ordinal Outcomes in Vascular Prevention Trials: Comparison With Binary Outcomes in Published Trials * Supplemental Appendix I: Statistical Tests Compared * Supplemental Appendix II: Supplementary Analyses * Supplemental Appendix III: Results
Bath et al.
Stroke 2008;39:2817-2823.
ABSTRACT | FULL TEXT  

Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
Hohnloser et al.
Eur Heart J Suppl 2008;10:H4-H10.
ABSTRACT | FULL TEXT  

Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Patrono et al.
Chest 2008;133:199S-233S.
ABSTRACT | FULL TEXT  

Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke Risk in Atrial Fibrillation Working Group
Stroke 2008;39:1901-1910.
ABSTRACT | FULL TEXT  

Stroke and Its Prevention in Chronic Kidney Disease
Khella and Bleicher
CJASN 2007;2:1343-1351.
ABSTRACT | FULL TEXT  

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
Hart et al.
ANN INTERN MED 2007;146:857-867.
ABSTRACT | FULL TEXT  

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Writing Committee Members et al.
Europace 2006;8:651-745.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:854-906.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:e149-e246.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:e257-e354.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:700-752.
FULL TEXT  

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Authors/Task Force Members et al.
Eur Heart J 2006;27:1979-2030.
FULL TEXT  

Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study)
Friberg et al.
Eur Heart J 2006;27:1954-1964.
ABSTRACT | FULL TEXT  

Relationship of Atrial Fibrillation and Stroke After Coronary Artery Bypass Graft Surgery: When is Anticoagulation Indicated?
Kollar et al.
Ann. Thorac. Surg. 2006;82:515-523.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation
Chan et al.
J Am Coll Cardiol 2006;47:2513-2520.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Circulation 2006;113:e873-e923.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Stroke 2006;37:1583-1633.
ABSTRACT | FULL TEXT  

Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation
Waldo et al.
J Am Coll Cardiol 2005;46:1729-1736.
ABSTRACT | FULL TEXT  

Are Transthoracic Echocardiographic Parameters Associated With Atrial Fibrillation Recurrence or Stroke?: Results From the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
Olshansky et al.
J Am Coll Cardiol 2005;45:2026-2033.
ABSTRACT | FULL TEXT  

The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors
Gersh et al.
Eur Heart J Suppl 2005;7:C5-C11.
ABSTRACT | FULL TEXT  

Current status of stroke prevention in patients with atrial fibrillation
Bath et al.
Eur Heart J Suppl 2005;7:C12-C18.
ABSTRACT | FULL TEXT  

Emerging therapies for stroke prevention in atrial fibrillation
O'Donnell et al.
Eur Heart J Suppl 2005;7:C19-C27.
ABSTRACT | FULL TEXT  

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study
Perez-Gomez et al.
J Am Coll Cardiol 2004;44:1557-1566.
ABSTRACT | FULL TEXT  

Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin
Gage et al.
Circulation 2004;110:2287-2292.
ABSTRACT | FULL TEXT  

Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry
Steger et al.
Eur Heart J 2004;25:1734-1740.
ABSTRACT | FULL TEXT  

Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Patrono et al.
Chest 2004;126:234S-264S.
ABSTRACT | FULL TEXT  

Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation
Conway et al.
J Am Coll Cardiol 2004;43:2075-2082.
ABSTRACT | FULL TEXT  

A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study
Wang et al.
JAMA 2003;290:1049-1056.
ABSTRACT | FULL TEXT  

New strategies in the surgical treatment of atrial fibrillation
Sie et al.
Cardiovasc Res 2003;58:501-509.
ABSTRACT | FULL TEXT  

Lessons from the Stroke Prevention in Atrial Fibrillation Trials
Hart et al.
ANN INTERN MED 2003;138:831-838.
ABSTRACT | FULL TEXT  

Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?
Bo et al.
Heart 2003;89:553-554.
FULL TEXT  

A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin
van Walraven et al.
Arch Intern Med 2003;163:936-943.
ABSTRACT | FULL TEXT  

Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?
Rutten et al.
Fam Pract 2003;20:16-21.
ABSTRACT | FULL TEXT  

Atrial fibrillation and heart failure: natural history and pharmacological treatment
Savelieva and John Camm
Europace 2003;5:S5-S19.
ABSTRACT | FULL TEXT  

Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis
van Walraven et al.
JAMA 2002;288:2441-2448.
ABSTRACT | FULL TEXT  

New insights into the mechanisms and management of atrial fibrillation
Khairy and Nattel
CMAJ 2002;167:1012-1020.
ABSTRACT | FULL TEXT  

An assessment of guidelines for prevention of ischemic stroke
Hart and Bailey
Neurology 2002;59:977-982.
ABSTRACT | FULL TEXT  

Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors
Conway et al.
Circulation 2002;106:1962-1967.
ABSTRACT | FULL TEXT  

Occurrence of Hemispheric and Retinal Ischemia in Atrial Fibrillation Compared With Carotid Stenosis * Editorial Comment
Anderson et al.
Stroke 2002;33:1963-1968.
ABSTRACT | FULL TEXT  

Management of the Older Person With Atrial Fibrillation
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M352-363.
ABSTRACT | FULL TEXT  

ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Fuster et al.
Circulation 2001;104:2118-2150.
FULL TEXT  

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur Heart J 2001;22:1852-1923.
 

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Fuster et al.
J Am Coll Cardiol 2001;38:1266-1266.
FULL TEXT  

Long term anticoagulation or antiplatelet treatment
Cleland et al.
BMJ 2001;323:233-233.
FULL TEXT  

Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage et al.
JAMA 2001;285:2864-2870.
ABSTRACT | FULL TEXT  

New-Onset Atrial Fibrillation : Sex Differences in Presentation, Treatment, and Outcome
Humphries et al.
Circulation 2001;103:2365-2370.
ABSTRACT | FULL TEXT  

Atrial Fibrillation
Falk
NEJM 2001;344:1067-1078.
FULL TEXT  

Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation
Klein et al.
J Am Coll Cardiol 2001;37:691-704.
ABSTRACT | FULL TEXT  

Atrial Fibrillation and Stroke : Concepts and Controversies
Hart and Halperin
Stroke 2001;32:803-808.
FULL TEXT  

Epidemiology and natural history of atrial fibrillation: clinical implications
Chugh et al.
J Am Coll Cardiol 2001;37:371-378.
ABSTRACT | FULL TEXT  

Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Patrono et al.
Chest 2001;119:39S-63S.
FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation
Albers et al.
Chest 2001;119:194S-206S.
FULL TEXT  

Geriatric Assessment and Anticoagulation in Elderly Patients With Chronic Atrial Fibrillation
Bellelli et al.
Arch Intern Med 2000;160:2402-2403.
FULL TEXT  

Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation : The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study
Go et al.
Circulation 2000;102:11-13.
ABSTRACT | FULL TEXT  

Anticoagulation for Chronic Atrial Fibrillation
Stern et al.
JAMA 2000;283:2901-2903.
FULL TEXT  

Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart and Pearce
ANN INTERN MED 2000;132:841-842.
FULL TEXT  

The Quality of Anticoagulation Management
Ansell
Arch Intern Med 2000;160:895-896.
FULL TEXT  

Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy
Hart et al.
J Am Coll Cardiol 2000;35:183-187.
ABSTRACT | FULL TEXT  

Reviews: Atrial Fibrillation: Current and Future Strategies for Management
Burkart and Curtis
J CARDIOVASC PHARMACOL THER 2000;5:151-160.
 

Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation : Correlation With Stroke Among 1531 Participants in the Stroke Prevention in Atrial Fibrillation III Study
Feinberg et al.
Stroke 1999;30:2547-2553.
ABSTRACT | FULL TEXT  

Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young
HART
Heart 1999;82:539-540.
FULL TEXT  

Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand?
Deplanque et al.
Heart 1999;82:563-569.
ABSTRACT | FULL TEXT  

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin
Hellemons et al.
BMJ 1999;319:958-964.
ABSTRACT | FULL TEXT  

A Patient Decision Aid Regarding Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: A Randomized Controlled Trial
Man-Son-Hing et al.
JAMA 1999;282:737-743.
ABSTRACT | FULL TEXT  

Evidence based cardiology: Prevention of ischaemic stroke
Barnett et al.
BMJ 1999;318:1539-1543.
FULL TEXT  

Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation : Analysis of 2012 Participants in the SPAF I–III Clinical Trials
Hart et al.
Stroke 1999;30:1223-1229.
ABSTRACT | FULL TEXT  

Lone Atrial Fibrillation in Elderly Persons: A Marker for Cardiovascular Risk
Kopecky et al.
Arch Intern Med 1999;159:1118-1122.
ABSTRACT | FULL TEXT  

Preventing Stroke in Patients With Atrial Fibrillation
Ezekowitz and Levine
JAMA 1999;281:1830-1835.
ABSTRACT | FULL TEXT  

Warfarin vs Aspirin and AFASAK 2
Bloom et al.
Arch Intern Med 1999;159:1010-1011.
FULL TEXT  

Aortic Plaque in Atrial Fibrillation : Prevalence, Predictors, and Thromboembolic Implications
Blackshear et al.
Stroke 1999;30:834-840.
ABSTRACT | FULL TEXT  

Patients With Atrial Fibrillation at Low Risk of Stroke
Cheung et al.
JAMA 1998;280:882-883.
FULL TEXT  

Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: Warfarin, Aspirin, or Both?
Albers
Arch Intern Med 1998;158:1487-1491.
FULL TEXT  

AF and Stroke II: When Is Aspirin Enough?
JWatch Emergency Med. 1998;1998:9-9.
FULL TEXT  

Identifying AF Patients at Low Risk for Stroke
Journal Watch Cardiology 1998;1998:1-1.
FULL TEXT  

Aspirin Reasonable for Low-Risk Atrial Fibrillation Patients
JWatch General 1998;1998:2-2.
FULL TEXT  

Stroke Treatment: Promising but Still Struggling
Caplan
JAMA 1998;279:1304-1306.
FULL TEXT